133 related articles for article (PubMed ID: 24487381)
1. Fcγ receptor IIIA genotype is associated with rituximab response in antimyelin-associated glycoprotein neuropathy.
Stork AC; Notermans NC; van den Berg LH; Schellevis RD; Niermeijer JM; Nederend M; Leusen JH; van der Pol WL
J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):918-20. PubMed ID: 24487381
[TBL] [Abstract][Full Text] [Related]
2. [Polymorphisms of FcγRIIA, FcγRIIIA and FcγRIIB in patients with immune thrombocytopenia and their clinical significance].
Zhu Y; Zhuang Y; Yang GH; Qiang XF; Yang L; Shen YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):135-9. PubMed ID: 23484707
[TBL] [Abstract][Full Text] [Related]
3. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.
Léger JM; Viala K; Nicolas G; Créange A; Vallat JM; Pouget J; Clavelou P; Vial C; Steck A; Musset L; Marin B;
Neurology; 2013 Jun; 80(24):2217-25. PubMed ID: 23667063
[TBL] [Abstract][Full Text] [Related]
4. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.
Hatjiharissi E; Hansen M; Santos DD; Xu L; Leleu X; Dimmock EW; Ho AW; Hunter ZR; Branagan AR; Patterson CJ; Kortsaris A; Verselis S; Fox E; Treon SP
Clin Lymphoma Myeloma; 2007 Jan; 7(4):286-90. PubMed ID: 17324336
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.
Galimberti S; Palumbo GA; Caracciolo F; Benedetti E; Pelosini M; Brizzi S; Ciabatti E; Fazzi R; Stelitano C; Quintana G; Conte E; Tibullo D; Di Raimondo F; Petrini M
J Chemother; 2007 Jun; 19(3):315-21. PubMed ID: 17594928
[TBL] [Abstract][Full Text] [Related]
6. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
[TBL] [Abstract][Full Text] [Related]
7. FcgammaRIIa, IIIa and IIIb gene polymorphisms in Behçet's disease: do they have any clinical implications?
Aksu K; Kitapcioglu G; Keser G; Berdeli A; Karabulut G; Kobak S; Ozmen M; Inal V; Kabasakal Y; Oksel F; Kocanaogullari H; Doganavsargil E
Clin Exp Rheumatol; 2008; 26(4 Suppl 50):S77-83. PubMed ID: 19026120
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.
Weng WK; Negrin RS; Lavori P; Horning SJ
J Clin Oncol; 2010 Jan; 28(2):279-84. PubMed ID: 19933905
[TBL] [Abstract][Full Text] [Related]
9. FcgammaRIIa/IIIa polymorphism and its association with clinical manifestations in Korean lupus patients.
Yun HR; Koh HK; Kim SS; Chung WT; Kim DW; Hong KP; Song GG; Chang HK; Choe JY; Bae SC; Salmon JE; Yoo DH; Kim TY; Kim SY
Lupus; 2001; 10(7):466-72. PubMed ID: 11480843
[TBL] [Abstract][Full Text] [Related]
10. [Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].
Qu YH; Li Y; Wu YF; Fang JP; Huang SL; Huang Y; Wei J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1269-74. PubMed ID: 21129274
[TBL] [Abstract][Full Text] [Related]
11. Association of the leukocyte immunoglobulin G (Fcgamma) receptor IIIa-158V/F polymorphism with inflammatory myopathies in Dutch patients.
Bronner IM; Hoogendijk JE; de Visser M; van de Vlekkert J; Badrising UA; Wintzen AR; Uitdehaag BM; Blokland-Fromme M; Leusen JH; van der Pol WL
Tissue Antigens; 2009 Jun; 73(6):586-9. PubMed ID: 19493236
[TBL] [Abstract][Full Text] [Related]
12. Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.
Angsirisak N; Wittayalertpanya S; Limpanasithikul W; Bunworasate U; Owattanapanich D
J Med Assoc Thai; 2015 Dec; 98(12):1215-21. PubMed ID: 27004307
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
Iancu Ferfoglia R; Guimarães-Costa R; Viala K; Musset L; Neil J; Marin B; Léger JM
J Peripher Nerv Syst; 2016 Mar; 21(1):10-4. PubMed ID: 26748872
[TBL] [Abstract][Full Text] [Related]
14. Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy.
Cornec D; Tempescul A; Querellou S; Hutin P; Pers JO; Jamin C; Bendaoud B; Berthou C; Renaudineau Y; Youinou P
Ann Hematol; 2012 May; 91(5):715-721. PubMed ID: 22083514
[TBL] [Abstract][Full Text] [Related]
15. Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma.
Zhang W; Wang X; Li J; Duan MH; Zhou DB
Chin Med J (Engl); 2010 Jan; 123(2):198-202. PubMed ID: 20137370
[TBL] [Abstract][Full Text] [Related]
16. Widening of myelin lamellae in polyneuropathy with immunoglobulin-M monoclonal gammopathy, without activity against myelin-associated glycoprotein, responsive to treatment.
Vallat JM; Deschamps N; Richard L; Magy L; Devaux J; Mathis S
Neuromuscul Disord; 2022 Aug; 32(8):678-681. PubMed ID: 35618575
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for polyneuropathy with IgM monoclonal gammopathy.
Niermeijer JM; Eurelings M; Lokhorst HL; van der Pol WL; Franssen H; Wokke JH; Notermans NC
J Neurol Neurosurg Psychiatry; 2009 Sep; 80(9):1036-9. PubMed ID: 19684235
[TBL] [Abstract][Full Text] [Related]
18. Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse.
Dijstelbloem HM; Scheepers RH; Oost WW; Stegeman CA; van der Pol WL; Sluiter WJ; Kallenberg CG; van de Winkel JG; Tervaert JW
Arthritis Rheum; 1999 Sep; 42(9):1823-7. PubMed ID: 10513795
[TBL] [Abstract][Full Text] [Related]
19. FcgammaRIIa-131R allele and FcgammaRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy.
Tanaka Y; Suzuki Y; Tsuge T; Kanamaru Y; Horikoshi S; Monteiro RC; Tomino Y
Nephrol Dial Transplant; 2005 Nov; 20(11):2439-45. PubMed ID: 16221721
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab.
Weng WK; Levy R
Leuk Lymphoma; 2009 May; 50(5):723-7. PubMed ID: 19452316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
